Piramal Pharma gains on receiving EIR from USFDA for Turbhe facility
Piramal Pharma is currently trading at Rs. 209.25, up by 1.35 points or 0.65% from its previous closing of Rs. 207.90 on the BSE.
The scrip opened at Rs. 210.25 and has touched a high and low of Rs. 213.65 and Rs. 207.30 respectively. So far 234393 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 307.85 on 06-Nov-2024 and a 52 week low of Rs. 135.85 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs. 217.00 and Rs. 200.55 respectively. The current market cap of the company is Rs. 27688.25 crore.
The promoters holding in the company stood at 34.95%, while Institutions and Non-Institutions held 46.26% and 18.78% respectively.
Piramal Pharma has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Turbhe facility with VAI (Voluntary Action Indicated). Receipt of said EIR marks successful closure of the inspection.
Earlier, the USFDA had conducted General Good Manufacturing Practices (GMP) inspection at company’s Turbhe facility from February 11, 2025 to February 17, 2025.
Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
